

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: James Martin Lenhard

Serial No.: To be assigned

Filed: Concurrently herewith

For:

METHODS OF SCREENING PROTEASE INHIBITORS, OF INDUCING MICE SUSCEPTIBLE TO HIV PROTEASE INHIBITOR-INDUCED DYSLIPIDEMIA,

AND GENES ASSOCIATED THEREWITH

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[] Copies of the references are enclosed

[] Copies of the references were submitted in parent application Serial No. _______. (37 CFR 1.98(d))

[X]A copy of the International Search Report which issued on International Application No. _______ PCT/US00/01205 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449. (37 CFR 1.98(d)), and applicants understand that copies have been supplied to the USPTO by the International Bureau.

- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,

whichever occurs first.

ſ	1	Applicant hereby certifies that each item of information contained in this Information Disclosure
	-	Statement was cited in a communication from a foreign patent office in a counterpart foreign
		application not more than three months prior to the filing of this statement.

- [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).
- C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.



JC03 Rec'd PCT/PTL 1 7 JUL 2001

In accordance with the requirements of 37 CFR 1.97(d):

Statement was cited in a communi	ch item of information contained in this Information Disclosure ication from a foreign patent office in a counterpart foreign onths prior to the filing of this statement.									
[] Applicant hereby petitions for the Statement. 37 CFR 1.97(d)(ii).	[] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).									
[] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.										
[X] Please charge required fees to Deposit Acc [] A duplicate copy of this paper is attached.	count No. 07-1392.									
Date: 17 July 2001	Respectfully Submitted,									
	Elizabeth Selby Attorney of Record, Reg. No. 38 298									

GlaxoSmithKline Corporate Intellectual Property Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709 (919) 483-3934

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)


I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

Date: 17 July 2001

Manuly Sldnidge

Marilyn Eldridge





FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. PG3610USW		SERIAL NO. To be assigned 947 1		
					APPLICANT James Martin Lenhard				
					FILING DATE Concurrently h		GROUP		
			U.S. PA	TENT D	OCUMENTS				
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate	
		·		<u> </u>					
] .		Cor	ntinue on	page				
					T DOCUMENTS	S			
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No	
	 								
	J		Cor	ntinue on	page		1 174- >		
		HER DOCUMI	ENTS (Includin	g Author	, Title, Journal-I	Jate, Page Ni	umber, Etc.)	Resistance	
	CA	in Patients Receiving HIV Protease Inhibitors, AIDS, 12(7):F51-F58 (1998)							
	CB	Hyperlipidaemia, and Insulin Resistance, Lancet, 351:1881-1883 (1998)							
	CC	Shaw, A.J. et al., Disorders of Fat Distribution in HIV Infection, International Journal of STD & AIDS, 9:595-599 (1998)							
	CD	Shimomura, I. et al., Insulin Resistance and Diabetes Mellitus in Transgenic Mice Expressing Nuclear SREBP-1c in Adipose Tissue: Model for Congenital Generalized Lipodystrophy, Genes & Development, 12:3182-3194 (1998)							
		Development,	12.3162-3194 (1	<i>)</i>					
	 					<u> </u>			
	+	,							
	+								
								_	
	1		-	-					
		<u> </u>							
		<u> </u>	Co	ontinue or	n page				
EXAMINI	ER					DATE	CONSIDEREI)	
EXAMINI through ci- applicant.	ER: Intation i	itial if citation co	nsidered, whether	er or not o	citation is in confo Include copy of the	ormance with	MPEP § 609; I next communic	Oraw line ation to the	